I β-bloccanti: Nuova prospettiva terapeutica per il melanoma

Translated title of the contribution: β-blockers: A new and emerging treatment for melanoma

Vincenzo De Giorgi, Sara Gandini, Marta Grazzini, Silvia Benemei, Niccolò Marchionni, Pierangelo Geppetti

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

Recent studies have underlined the innovative theories concerning the role of neuroendocrine system on the tumor and metastasis microenvironment. These observations have suggested the possibility that drugs originally intended for the treatment of cardiovascular disease, the β-adrenergic receptor blockers (β-blockers), may provide new therapeutic opportunities for the control of tumor progression. A large number of observational studies showed the protective effect of β-blockers in breast cancer, but more recently, similar findings were also reported in other cancers such as prostate cancer and melanoma. The results of these studies have shown that the use of β-blockers, but not other antihypertensive drugs, was associated with a significant increase of the disease free survival and of the overall survival. With regard to melanoma, a recent study by De Giorgi et al. showed a 36% reduction in risk of disease progression for each year of treatment with β-blockers. These data, originating from prospective studies, cannot be considered conclusive and require validation by means of clinical trials that are underway.

Original languageItalian
Pages (from-to)11-16
Number of pages6
JournalRecenti Progressi in Medicina
Volume103
Issue number1
Publication statusPublished - Jan 2012

Fingerprint

Melanoma
Neurosecretory Systems
Adrenergic Antagonists
Tumor Microenvironment
Risk Reduction Behavior
Adrenergic Receptors
Antihypertensive Agents
Disease-Free Survival
Observational Studies
Disease Progression
Neoplasms
Prostatic Neoplasms
Cardiovascular Diseases
Clinical Trials
Prospective Studies
Breast Neoplasms
Neoplasm Metastasis
Pharmaceutical Preparations
Therapeutics

ASJC Scopus subject areas

  • Medicine(all)

Cite this

De Giorgi, V., Gandini, S., Grazzini, M., Benemei, S., Marchionni, N., & Geppetti, P. (2012). I β-bloccanti: Nuova prospettiva terapeutica per il melanoma. Recenti Progressi in Medicina, 103(1), 11-16.

I β-bloccanti : Nuova prospettiva terapeutica per il melanoma. / De Giorgi, Vincenzo; Gandini, Sara; Grazzini, Marta; Benemei, Silvia; Marchionni, Niccolò; Geppetti, Pierangelo.

In: Recenti Progressi in Medicina, Vol. 103, No. 1, 01.2012, p. 11-16.

Research output: Contribution to journalArticle

De Giorgi, V, Gandini, S, Grazzini, M, Benemei, S, Marchionni, N & Geppetti, P 2012, 'I β-bloccanti: Nuova prospettiva terapeutica per il melanoma', Recenti Progressi in Medicina, vol. 103, no. 1, pp. 11-16.
De Giorgi V, Gandini S, Grazzini M, Benemei S, Marchionni N, Geppetti P. I β-bloccanti: Nuova prospettiva terapeutica per il melanoma. Recenti Progressi in Medicina. 2012 Jan;103(1):11-16.
De Giorgi, Vincenzo ; Gandini, Sara ; Grazzini, Marta ; Benemei, Silvia ; Marchionni, Niccolò ; Geppetti, Pierangelo. / I β-bloccanti : Nuova prospettiva terapeutica per il melanoma. In: Recenti Progressi in Medicina. 2012 ; Vol. 103, No. 1. pp. 11-16.
@article{7f25649a111f4a9db9502c0506a991d4,
title = "I β-bloccanti: Nuova prospettiva terapeutica per il melanoma",
abstract = "Recent studies have underlined the innovative theories concerning the role of neuroendocrine system on the tumor and metastasis microenvironment. These observations have suggested the possibility that drugs originally intended for the treatment of cardiovascular disease, the β-adrenergic receptor blockers (β-blockers), may provide new therapeutic opportunities for the control of tumor progression. A large number of observational studies showed the protective effect of β-blockers in breast cancer, but more recently, similar findings were also reported in other cancers such as prostate cancer and melanoma. The results of these studies have shown that the use of β-blockers, but not other antihypertensive drugs, was associated with a significant increase of the disease free survival and of the overall survival. With regard to melanoma, a recent study by De Giorgi et al. showed a 36{\%} reduction in risk of disease progression for each year of treatment with β-blockers. These data, originating from prospective studies, cannot be considered conclusive and require validation by means of clinical trials that are underway.",
keywords = "β-blockers, Hypertension, Melanoma, Propranolol, Prostate cancer",
author = "{De Giorgi}, Vincenzo and Sara Gandini and Marta Grazzini and Silvia Benemei and Niccol{\`o} Marchionni and Pierangelo Geppetti",
year = "2012",
month = "1",
language = "Italian",
volume = "103",
pages = "11--16",
journal = "Recenti Progressi in Medicina",
issn = "0034-1193",
publisher = "Il Pensiero Scientifico Editore s.r.l.",
number = "1",

}

TY - JOUR

T1 - I β-bloccanti

T2 - Nuova prospettiva terapeutica per il melanoma

AU - De Giorgi, Vincenzo

AU - Gandini, Sara

AU - Grazzini, Marta

AU - Benemei, Silvia

AU - Marchionni, Niccolò

AU - Geppetti, Pierangelo

PY - 2012/1

Y1 - 2012/1

N2 - Recent studies have underlined the innovative theories concerning the role of neuroendocrine system on the tumor and metastasis microenvironment. These observations have suggested the possibility that drugs originally intended for the treatment of cardiovascular disease, the β-adrenergic receptor blockers (β-blockers), may provide new therapeutic opportunities for the control of tumor progression. A large number of observational studies showed the protective effect of β-blockers in breast cancer, but more recently, similar findings were also reported in other cancers such as prostate cancer and melanoma. The results of these studies have shown that the use of β-blockers, but not other antihypertensive drugs, was associated with a significant increase of the disease free survival and of the overall survival. With regard to melanoma, a recent study by De Giorgi et al. showed a 36% reduction in risk of disease progression for each year of treatment with β-blockers. These data, originating from prospective studies, cannot be considered conclusive and require validation by means of clinical trials that are underway.

AB - Recent studies have underlined the innovative theories concerning the role of neuroendocrine system on the tumor and metastasis microenvironment. These observations have suggested the possibility that drugs originally intended for the treatment of cardiovascular disease, the β-adrenergic receptor blockers (β-blockers), may provide new therapeutic opportunities for the control of tumor progression. A large number of observational studies showed the protective effect of β-blockers in breast cancer, but more recently, similar findings were also reported in other cancers such as prostate cancer and melanoma. The results of these studies have shown that the use of β-blockers, but not other antihypertensive drugs, was associated with a significant increase of the disease free survival and of the overall survival. With regard to melanoma, a recent study by De Giorgi et al. showed a 36% reduction in risk of disease progression for each year of treatment with β-blockers. These data, originating from prospective studies, cannot be considered conclusive and require validation by means of clinical trials that are underway.

KW - β-blockers

KW - Hypertension

KW - Melanoma

KW - Propranolol

KW - Prostate cancer

UR - http://www.scopus.com/inward/record.url?scp=84856775782&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84856775782&partnerID=8YFLogxK

M3 - Articolo

C2 - 22322621

AN - SCOPUS:84856775782

VL - 103

SP - 11

EP - 16

JO - Recenti Progressi in Medicina

JF - Recenti Progressi in Medicina

SN - 0034-1193

IS - 1

ER -